Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy

Matos, Patrícia Francisca de; Ferreira, Ana Paula C; Facuri, F de Oliveira; Assumpção, Lígia Vera Montali da; Metze, Konradin; Ward, Laura Sterian

doi:10.1111/j.1365-2559.2005.02221.x

Cited by 173 publications

(179 citation statements)

References 27 publications

Supporting

Mentioning

144

Contrasting

Unclassified

Order By: Relevance

“…CK19 is a low molecular weight cytokeratin which is expressed in various epithelial tissues and tumors [10]. While there are differences among studies in terms of the extensiveness and intensity of its expression in follicular epithelial cell derived lesions of the thyroid, it is more diffused and stronger in papillary carcinoma [5,8,9,10]. Additionally, it is known to be positively stained also in benign nodules and follicular adenoma [7,8].…”

Section: Discussionmentioning

confidence: 99%

“…There are numerous studies reporting its advantages in determining malignancy in thyroid nodules derived from follicular epithelial cells [5,8,10,21]. Moreover, there are also studies showing HBME-1 as positive in benign thyroid lesions such as chronic lymphocytic thyroiditis, benign thyroid nodules and follicular adenoma [7,9,22]. While Cheung et al did not find positivity with HBME-1 in any of the benign thyroid nodules and cases of follicular adenoma, they found positivity in 55% of cases with papillary carcinoma, 70% in CVPTC, and only 45% in FVPTC [5].…”

Section: Discussionmentioning

confidence: 99%

“…Correct pathological diagnosis is necessary to minimize emotional stress, over-treatments and related financial costs brought by the diagnosis of thyroid cancer [3]. In order to eliminate disagreements among pathologists about well-differentiated lesions of thyroid derived from follicular epithelial cells and achieve diagnostic standardization, there have been many studies made where immunohistochemical and molecular markers are studied [4,5,6,7,8,9,10,11,12]. The immunohistochemical markers Hector Battifora mesothelial cell epitope-1 (HBME-1), galectin 3 (Gal-3) and cytokeratin 19 (CK19) accepted to be indicators of malignancy in thyroid lesions have been used as products of such studies as panels in most pathology laboratories.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

In this study, we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3. We selected 102 cases from our archive including 20 normal thyroid tissues, 23 follicular nodular diseases, 17 follicular adenomas, 20 follicular variant papillary carcinomas and 22 classical variant papillary carcinomas. Tissue microarrays constructed from these cases were immunohistochemically analyzed with HBME-1, CK19, galectin-3 and TROP-2. Respectively 73.8%, 83.3%, 69% and 50% of all papillary carcinomas were positive with HBME-1, CK19, galectin-3 and TROP-2. CK19 was positive respectively by 100%, 43.5% and 35.3% in cases of normal thyroid, follicular nodular diseases and follicular adenoma, while the other markers were negative. In distinguishing benign and malignant lesions, which constitutes this study, HBME-1, CK19, galectin-3 and TROP-2 were statistically significant (p < 0.001). In distinguishing cases of follicular variant papillary carcinoma from follicular nodular diseases and follicular adenoma, HBME-1 and galectin-3 were statistically significant (p < 0.001). Consequently, in this study, we found that all immunohistochemical markers were effective in distinguishing benign and malignant thyroid lesions. In determining malignancy, HBME-1 had the highest diagnostic accuracy, while CK19 was the most sensitive marker. The sensitivity increased when the markers were used together.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

show abstract

“…A number of immunohistochemical approaches have been applied to indeterminate cytology specimens in an effort to reclassify these samples, including galectin-3, HBME-1, and CK19 (33,34). This approach is best at identifying classic PTC, but sensitivity progressively declines when one encounters fvPTC, FTC, and less common malignant variants.…”

Section: Application Of Immunohistochemistry To Fna Cytologymentioning

confidence: 99%

Molecular markers in the diagnosis of thyroid nodules

Ward

Kloos²

2013

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

SUMMARYAn indeterminate thyroid nodule cytology result occurs about every sixth fine-needle aspiration. These indeterminate nodules harbor a 24% risk of malignancy (ROM); too high to ignore, but driving surgery where most nodules are benign. Molecular diagnostics have emerged to ideally avoid surgery when appropriate, and to trigger the correct therapeutic surgery when indicated, as opposed to an incomplete diagnostic surgery. No current molecular test offers both high sensitivity and high specificity. A molecular diagnostic test with high sensitivity (e.g. Afirma Gene Expression Classifier sensitivity 90%) offers a high Negative Predictive Value when the ROM is relatively low, such as < 30%. Only such tests can "rule-out" cancer. In this setting, a molecularly benign result suggests the same ROM as that of operated cytologically benign nodules (~6%). Thus, clinical observation can replace diagnostic surgery; increasing quality of life and decreasing medical costs. However, its low specificity cannot "rule-in" cancer as a suspicious result has a Positive Predictive Value (PPV) of ~40%, perhaps too low to routinely reflex to definitive cancer surgery. Conversely, high specificity tests (BRAF, RAS, PPAR/PAX-8, RET/PTC, PTEN) offer high PPV results, and only these tests can "rule-in" cancer. Here a positive molecular result warrants definitive therapeutic surgery. However, their low sensitivity cannot "rule-out" cancer and a negative molecular result cannot dissuade diagnostic surgery; limiting their cost-effectiveness. Whether or not there is a useful and cost-effective role to sequentially combine these approaches, or to modify existing approaches, is under investigation. Arq Bras Endocrinol Metab. 2013;57(2):89-97 Keywords Biopsy, fine-needle; DNA mutational analysis; gene expression; genomics; molecular diagnostic techniques SUMáRioResultados indeterminados na citologia de um nódulo tireoidiano ocorrem em cerca de um a cada seis punções aspirativas por agulha fina. Esses nódulos indeterminados apresentam risco de malignidade (RM) de cerca de 24%, um valor alto demais para ser ignorado e que leva à cirurgia em casos em que a maioria dos nódulos é benigna. O diagnóstico molecular é uma forma ideal de se evitar a cirurgia quando apropriado e de se levar ao correto procedimento cirúrgico terapêutico quando indicado, em oposição à cirurgia diagnóstica incompleta. Atualmente, não existem testes moleculares com alta sensibilidade e especificidade. Um teste molecular de alta sensibilidade (por exemplo, a sensibilidade do teste Afirma Gene Expression Classifier é de 90%) tem um alto Valor Preditivo Negativo quando o RM é relativamente baixo, por exemplo, < 30%. Apenas esses testes podem "excluir" o câncer. Nesse contexto, um resultado molecular benigno sugere o mesmo RM de nódulos com resultado benigno na citologia e operados (~6%). Assim, a observação clínica pode substituir a cirurgia diagnóstica, aumentando a qualidade de vida e diminuindo os custos médicos. Entretanto, a baixa especificidade não pode "incluir" o cân...

show abstract

“…Various molecular markers have been examined to improve the sensitivity and specificity of FNA cytology, and some of them are being used as test panels in the clinical practice. [5,6] The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) which are known markers of the systemic inflammatory response, have been associated with progression and survival in most cancers. [7,8] Therefore, we evaluated retrospectively the laboratory tests of our patients who underwent thyroid surgery.…”

mentioning

confidence: 99%

Predictive role of neutrophil-lymphocyte and platelet-lymphocyte ratios in thyroid nodules with cytological diagnosis of "undetermined significance" and "suspicious for malignancy"

Bayır¹,

Karagöz²,

Öcal³

et al. 2017

ENT Updates

View full text Add to dashboard Cite

Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy

Abstract: HBME-1 is the most sensitive marker for thyroid malignancy but the three markers may be useful in specific cases. This panel of markers is useful to differentiate the follicular patterned lesions, with special reference to the FVPC.

Cited by 173 publications

References 27 publications

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Molecular markers in the diagnosis of thyroid nodules

Predictive role of neutrophil-lymphocyte and platelet-lymphocyte ratios in thyroid nodules with cytological diagnosis of "undetermined significance" and "suspicious for malignancy"

Contact Info

Product

Resources

About